Pic

Agenus Inc.

$AGEN
$2.65
Капитализция: $796.2M
Показать больше информации о компании

О компании

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of показать больше
fully human and humanized monoclonal antibodies and display technologies. It develops vaccine programs comprising Prophage vaccine candidate and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial AGEN1777, an anti-TIGIT bispecific antibodies and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody INCAGN1949, an anti-OX40 monospecific antibody INCAGN2390, an anti-TIM-3 monospecific antibody INCAGN2385, an anti-LAG-3 monospecific antibody MK-4830, a monospecific antibody targeting ILT4 AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies and display technologies. It develops vaccine programs comprising Prophage vaccine candidate and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial AGEN1777, an anti-TIGIT bispecific antibodies and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody INCAGN1949, an anti-OX40 monospecific antibody INCAGN2390, an anti-TIM-3 monospecific antibody INCAGN2385, an anti-LAG-3 monospecific antibody MK-4830, a monospecific antibody targeting ILT4 AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Перевод автоматический

показать меньше

Отчетность

03.11.2021, 23:08 EPS за 3 квартал составил ХХ, консенсус YY

04.08.2021, 23:12 Прибыль на акцию за 2 квартал XX, консенсус-прогноз YY
Квартальная отчетность будет доступна после Регистрации

Прогнозы аналитиков

Аналитик Аарон Кесслер поддерживает с сильной покупкой и снижает целевую цену со xxx до yyy долларов.

25.10.2021, 16:02 Аналитик Berenberg Сунил Райгопал инициирует освещение на GoDaddy с рейтингом «Покупать» и объявляет целевую цену в xxx долларов.
Прогнозы аналитиков будут доступны после Регистрации

Все новости компании Agenus

Новости переведены автоматически

Попробуйте все возможности сервиса Tradesense

Моментальные уведомления об измемении цен акций
Новости с официальных сайтов компаний
Отчётности компаний
События с FDA, SEC
Прогнозы аналитиков и банков
Регистрация в сервисе
Tradesense доступен на мобильных платформах